Latest News

Aagami receives Contract Extension and Expansion of scope from NYC Biotech client

We are pleased to announce that Aagami has received Contract Extension and Expansion of scope from its US based client. The client is an Awa...

Published : 20 Feb 2024

Read More

Aagami CEO to attend DCAT week 2024 in New York City (March 18-21)

We are pleased to announce that Aagami CEO Dinesh Jain will be attending DCAT Week 2023 in person from MARCH 18 to 21 in New York City. If you or your...

Published : 09 Feb 2024

Read More

Client with Market and Late stage Biosimilars awards contract extension to Aagami.

Several months back, a Biosimilar focused subsidiary of a Global Pharma had appointed Aagami to help out-license their Market ready Denosumab Biosimil...

Published : 19 Jan 2024

Read More

Aagami receives extension from Nose to brain delivery Client developing drugs targeting Frontotemporal Dementia and other neurodegenerative diseases

We are pleased to announce that Aagami has received contract extension from its Japan and US based client.  Client is a nose to brain [NtoB]...

Published : 10 Jan 2024

Read More

New Assignment: Acquisition/Partnering for a Patented small molecule NSAID combination for Migraine using 505(b)(2)

Happy with the delivery of the first Assignment, our US based client has now appointed Aagami for Acquisition/Partnering for their Patented s...

Published : 12 Dec 2023

Read More

Aagami VP Godwyn Francis successfully completed an Action packed Bio Europe 2023 in Munich

Continuing with its annual tradition, Aagami completed an action packed and productive Bio Europe in Munich (Nov 6-8, 2023). This time Aagami and...

Published : 14 Nov 2023

Read More

Aagami to attend JPM week 2024 in San Francisco

JP Morgan Healthcare (JPM) week is an annual pilgrimage for Aagami and hence the team is already geared up for participation including Biotech Showcas...

Published : 22 Oct 2023

Read More

New Client Win: Innovator addressing migraine and other indications such as pain, fever, and dysmenorrhea

A US based Innovator has appointed Aagami for evaluation of his Intellectual Property of two patent families and the underlying technology. The o...

Published : 27 Aug 2023

Read More

New Assignment: Existing client from New York has appointed Aagami for supporting strategic Initiatives of their new subsidiary focus on Innovation in Autoimmune diseases

Aagami has a new client. This time it is a new subsidiary of an existing client from New York. The new client is focused on understanding the rol...

Published : 21 Aug 2023

Read More

Aagami to attend BIO-Europe 2023 in Munich, Germany

We are glad to announce that Aagami is attending the International Life Sciences Partnering Conference – BIO-Europe® 2023 (November ...

Published : 17 Aug 2023

Read More

×
Twitter